Our Take
California's life sciences sector is shrinking where it matters most (direct employment) while remaining economically massive on paper, a gap that reflects the lag between announced manufacturing deals and actual hiring.
Why it matters
Biotech and pharma leaders rely on California's talent density and supply chains. Job losses across San Francisco, San Diego, and LA signal investor caution during a period of federal policy uncertainty, tariffs, and pricing pressure that could reshape where companies choose to build.
Do this week
Life sciences hiring managers: audit your 2026 headcount plans against Newsom's proposed R&D tax credit cap (effective 2027), and model the cost of moving R&D or manufacturing if the cap passes.
California's Three Largest Biotech Hubs All Shed Jobs in 2025
California's life sciences industry employed 406,505 people in 2025 and generated $394 billion in economic output, according to BIOCOM California's report released during the BIO International Convention in San Diego. When counting indirect and induced economic activity, the sector sustained 1,079,365 jobs statewide (company-reported).
Yet all three of the state's dominant clusters contracted. The San Francisco Bay Area's life-sciences workforce fell 2.7% to 137,779 jobs, driven by losses in scientific research tools, biotech, and biopharmaceuticals. San Diego declined 2.55% to 61,866 jobs, primarily from R&D and electromedical apparatus manufacturing. Los Angeles, San Bernardino, and Ventura counties dropped 0.5% to 143,153 jobs. Orange County slipped 0.5% to 57,213 jobs (per BIOCOM California).
Manufacturing jobs, which represent 35.3% of all life-sciences employment in California, fell 2.1% to 143,572. Of 31 subsectors tracked, 23 recorded losses. Meanwhile, NIH funding to California remained flat at $5.23 billion year-over-year, but the number of NIH awards fell 8.5% from 9,384 to 8,587 (per BIOCOM California).
The Gap Between Announced Projects and Actual Hiring
The contraction masks a structural timing problem. Gilead Sciences began construction in September 2025 on a 180,000-square-foot facility as part of a $32 billion U.S. investment strategy. Novartis opened a 10,000-square-foot radioligand therapy manufacturing site in Carlsbad in November 2025. Major pharma and contract manufacturers have announced hundreds of billions in new projects, yet hiring has not risen to match because projects remain under construction (per BIOCOM California president Tim Scott).
The job losses reflect what Scott called a "continued biotech winter" driven by multiple federal headwinds: NIH funding cuts, delays in reauthorizing SBIR and STTR seed funding programs, tariffs, and the Trump administration's "most favored nation" drug pricing framework. These have caused investors and companies to pause.
Two regulatory threats compound the uncertainty. The Biotech Investment National Security Act (BINSA), introduced by Reps. John Moolenaar and Debbie Dingell, would expand outbound investment screening to pharmaceutical and biological product development, requiring U.S. Treasury Department review of pharma licensing deals, joint ventures, and equity investments with Chinese entities. The measure also directs the Secretary of Defense to assess within 60 days whether U.S. capital in Chinese biotech harms national security.
In Sacramento, Gov. Gavin Newsom has proposed capping annual business tax credits starting in 2027. Corporate taxpayers could claim a maximum of $5 million or 50% of pre-credit tax liability, whichever is greater. California's Legislative Analyst's Office estimates the R&D credit accounts for most of the fiscal impact and that roughly 100 large corporations, including major biopharma companies, would be affected (per LAO analysis).
What Hiring Managers and Corporate Strategy Teams Should Monitor
The R&D tax credit is a primary tool for attracting pharma investment to California. If the credit cap passes, companies will model the cost of relocating R&D or shifting manufacturing to states with stronger incentives. Biotech hiring leaders should stress-test their 2027–2030 headcount plans against a scenario in which the credit is capped and federal investment screening of China deals narrows partnerships or delays clinical collaborations.
Manufacturing leaders should separately track the timeline of announced projects (Gilead, Novartis, and others) and correlate them with regional hiring patterns. If these projects begin staffing within the next 12 months, job losses should reverse. If they stall due to tariff uncertainty or financing delays, the contraction may deepen.